BENGALURU, India - Biocon Limited announced on Nov. 16 that the U.S. Food and Drug Administration approved Pebrilzo (pertuzumab-qcay), a biosimilar to Roche's breast cancer drug Perjeta. Under a patent settlement with Genentech, the therapy's earliest licensed U.S. launch is the third quarter of 2028.
Indications Span Early and Metastatic Disease
Pebrilzo marks Biocon's fifth U.S. oncology biosimilar and the second pertuzumab biosimilar cleared by the FDA after Poherdy in November 2025. Approved for use alongside trastuzumab and chemotherapy, the monoclonal antibody treats adults with HER2-positive metastatic breast cancer and high-risk early-stage disease. "For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families," said Biocon CEO Shreehas Tambe.
Safety Warnings and 2028 Market Entry
The approval rests on analytical and comparative pharmacokinetic data showing no clinically meaningful differences from Perjeta in quality, safety, or efficacy. Like Perjeta, Pebrilzo carries boxed warnings for left ventricular dysfunction and embryo-fetal toxicity, requiring cardiac monitoring during treatment. Under Biocon's global license agreement with Genentech, commercial sales in the United States cannot begin until Q3 2028.



